Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis

BACKGROUND: Patients with cancer are at increased risk of venous thromboembolism (VTE) and the risk is further elevated after a primary VTE. To reduce the risk of recurrent events, extended prophylaxis with vitamin K antagonists (VKA) is available for use. However, in a large randomized trial (Compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Dranitsaris, George, Shane, Lesley G, Crowther, Mark, Feugere, Guillaume, Woodruff, Seth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237592/
https://www.ncbi.nlm.nih.gov/pubmed/28138260
http://dx.doi.org/10.2147/CEOR.S126379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237592/
https://www.ncbi.nlm.nih.gov/pubmed/28138260
http://dx.doi.org/10.2147/CEOR.S126379

Ejemplares similares